

Press Release

INVESTOR RELATIONS
Ashish Girotra
ashishg@drreddys.com
(Ph: +1 6093756145)

Contact:

MEDIA RELATIONS
Lori McCreary
lmccreary@drreddys.com
(Ph: +1 6093752995)

107 College Road East
Princeton, NJ 08540
www.promiuspharma.com

Promius Pharma Will Present Results of Additional Analysis of the American Migraine Prevalence and Prevention Study (AMPP) in Vancouver at the 68th AAN Annual Meeting, April 15–21, 2016

Princeton, NJ, USA. April 8, 2016 — Promius Pharma LLC announced today that it will present a poster titled “Predictors of Inadequate 24-Hour Sustained Response in Episodic Migraine: Results from American Migraine Prevalence and Prevention Study (AMPP)” in two sessions at the American Academy of Neurology (AAN) 68th Annual Meeting, to be held in Vancouver, BC, Canada, April 15–21, 2016.

From the 2006 AMPP Study respondents who met criteria for episodic migraine, the poster will report:

- The proportion usually pain-free 2 hours (2hPF) after acute treatment
- The proportion of these with sustained pain response at 24 hours (2hPF/24hSPR)
- Sociodemographic factors, lifestyle characteristics, headache features, and treatment patterns associated with inadequate responses to treatment

The poster presentations will show that among 8,333 adults, 44% reported an adequate 2-hour pain free response, and 74% of these achieved 24-hour sustained pain relief. In those with adequate 2-hour pain free response, the presence of allodynia, depression, medication overuse, and more frequent headache days were associated with greater likelihood of headache returning within 24 hours.

There will be two presentations of the poster at AAN 2016:

Presentation #1: I3:013

Session title: New and Emerging Therapeutic Options in Migraine and Other Headache Disorders

Session date: April 17, 2016

<http://www.abstractsonline.com/pp8/#!/4046/presentation/6380>

Presentation #2: P4.125

Session title: Headache: Imaging and Other

Session date: April 19, 2016

<http://www.abstractsonline.com/pp8/#!/4046/presentation/5557>

The lead author for the analysis is Sagar Munjal, MD, MS, Senior Director/Head of Neurology Clinical Development and Medical Affairs for Promius Pharma, a subsidiary of Dr. Reddy's Laboratories. The other authors are: Michael Reed, PhD (Vedanta Research, Chapel Hill, NC), Dawn Buse, PhD (Montefiore Medical Center & Albert Einstein College of Medicine, Bronx, NY), Alix Bennett, PhD

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.

Press Release

INVESTOR RELATIONS
Ashish Girotra
ashishg@drreddys.com
(Ph: +1 6093756145)

Contact:

MEDIA RELATIONS
Lori McCreary
lmccreary@drreddys.com
(Ph: +1 6093752995)

107 College Road East
Princeton, NJ 08540
www.promiuspharma.com

(Promius Pharma, a subsidiary of Dr. Reddy's Laboratories), Kristina Fanning, PhD (Vedanta Research, Chapel Hill, NC), and Richard Lipton, MD (Montefiore Medical Center & Albert Einstein College of Medicine, Bronx, NY).

About the AMPP Study

Migraine impacts millions of people, and sustained pain relief may be difficult to achieve, even among those who respond initially to treatment. The AMPP Study provides cross-sectional and longitudinal (2006 – 2009) mailed questionnaire data from a large sample of persons with severe headache and migraine in a sample selected to be representative of the US population. The AMPP Study obtained sociodemographics, headache features, comorbid health conditions, and other information.

About Promius Pharma LLC

Promius Pharma is a wholly owned subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients' needs in dermatology and neurology.

In January 2016, Promius Pharma received FDA approval for a product to treat acute migraine. Promius Pharma will be an exhibitor at AAN 2016 at the Vancouver convention center. Please visit our booth # 1450 and 1551. For more information, visit <http://www.promiuspharma.com/>.

Contact information:

Promius Pharma, LLC
107 College Rd E
Princeton, NJ 08540
www.promiuspharma.com

Investor Relations:
Ashish Girotra (USA)
ashishg@drreddys.com
+1 (609) 375-6145

Media Relations:
Lori McCreary (USA)
lmccreary@drreddys.com
+1 (609) 375-2995

Copyright 2016 Promius Pharma, LLC

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.